De Bruyn Frederik, Van Brempt Maarten, Maertens Jo, Van Bellegem Wouter, Duchi Dries, De Mey Marjan
Department of Biochemical and Microbial Technology, Centre of Expertise-Industrial Biotechnology and Biocatalysis, Ghent University, Coupure Links 653, 9000, Ghent, Belgium.
Microb Cell Fact. 2015 Sep 16;14:138. doi: 10.1186/s12934-015-0326-1.
Flavonoids are bio-active specialized plant metabolites which mainly occur as different glycosides. Due to the increasing market demand, various biotechnological approaches have been developed which use Escherichia coli as a microbial catalyst for the stereospecific glycosylation of flavonoids. Despite these efforts, most processes still display low production rates and titers, which render them unsuitable for large-scale applications.
In this contribution, we expanded a previously developed in vivo glucosylation platform in E. coli W, into an efficient system for selective galactosylation and rhamnosylation. The rational of the novel metabolic engineering strategy constitutes of the introduction of an alternative sucrose metabolism in the form of a sucrose phosphorylase, which cleaves sucrose into fructose and glucose 1-phosphate as precursor for UDP-glucose. To preserve these intermediates for glycosylation purposes, metabolization reactions were knocked-out. Due to the pivotal role of UDP-glucose, overexpression of the interconverting enzymes galE and MUM4 ensured the formation of both UDP-galactose and UDP-rhamnose, respectively. By additionally supplying exogenously fed quercetin and overexpressing a flavonol galactosyltransferase (F3GT) or a rhamnosyltransferase (RhaGT), 0.94 g/L hyperoside (quercetin 3-O-galactoside) and 1.12 g/L quercitrin (quercetin 3-O-rhamnoside) could be produced, respectively. In addition, both strains showed activity towards other promising dietary flavonols like kaempferol, fisetin, morin and myricetin.
Two E. coli W mutants were engineered that could effectively produce the bio-active flavonol glycosides hyperoside and quercitrin starting from the cheap substrates sucrose and quercetin. This novel fermentation-based glycosylation strategy will allow the economically viable production of various glycosides.
黄酮类化合物是具有生物活性的特殊植物代谢产物,主要以不同的糖苷形式存在。由于市场需求不断增加,已开发出各种生物技术方法,这些方法利用大肠杆菌作为微生物催化剂对黄酮类化合物进行立体特异性糖基化。尽管做出了这些努力,但大多数工艺的生产率和产量仍然很低,这使得它们不适用于大规模应用。
在本研究中,我们将先前在大肠杆菌W中开发的体内糖基化平台扩展为一个高效的选择性半乳糖基化和鼠李糖基化系统。这种新型代谢工程策略的原理是引入一种以蔗糖磷酸化酶形式存在的替代蔗糖代谢途径,该酶将蔗糖裂解成果糖和葡萄糖1-磷酸,作为UDP-葡萄糖的前体。为了将这些中间体保留用于糖基化目的,敲除了代谢反应。由于UDP-葡萄糖的关键作用,相互转化酶galE和MUM4的过表达分别确保了UDP-半乳糖和UDP-鼠李糖的形成。通过额外供应外源添加的槲皮素并过表达黄酮醇半乳糖基转移酶(F3GT)或鼠李糖基转移酶(RhaGT),分别可以产生0.94 g/L的金丝桃苷(槲皮素3-O-半乳糖苷)和1.12 g/L的芦丁(槲皮素3-O-鼠李糖苷)。此外,这两种菌株对其他有前景的膳食黄酮醇如山奈酚、非瑟酮、桑色素和杨梅素也有活性。
构建了两种大肠杆菌W突变体,它们可以从廉价底物蔗糖和槲皮素有效地生产生物活性黄酮醇糖苷金丝桃苷和芦丁。这种基于发酵的新型糖基化策略将使各种糖苷的经济可行生产成为可能。